Associate Director, KOL Engagement (Achondroplasia)

The Associate Director, KOL Management will support the development of a late-stage commercial asset, Infigratinib, the first and only oral therapy for the treatment of achondroplasia.

The individual will drive cross-functional collaboration and tactical alignment, ensuring success in the US.

They will lead the development of strategic and tactical KOL engagement plans.

Success will be measured by gaining and sharing of key insights, and the development of knowledge related to an asset and/or disease state and well as the development of mutually beneficial partnerships with relevant stakeholders.

This person will play a key strategic role on the commercial product team and partner closely with Market Insights, Regulatory, Medical Affairs, and other key stakeholders.

The role requires strong clinical acumen, communication and leadership skills, and the ability to influence across the organization.

Design KOL identification/profiling, mapping and key strategic efforts to establish engagement with and by KOLs in the cardiology space

Lead the creation, execution and maintenance of the commercial Key Opinion Leader engagement plan to build, cultivate and maintain KOL relationships

Develop resources for KOL engagement activities such as a database or similar platform for tracking of KOL partnership

Support development and management of the infigratinib speaker bureau, including program design, ongoing maintenance, speaker selection, and innovative strategies to strengthen brand messaging

Lead US Congress KOL engagement planning for the commercial team

Partner closely with internal teams to ensure we are using appropriate insights and metrics to inform the KOL management strategy and activities – directly to KOLs and with KOLs toward community physicians